Teva Pharmaceuticals has reportedly lost a battle to have a generic form of its multiple sclerosis drug be blocked from entering the market 10 days before Teva’s patent expires.
According to reports, the Israel-based pharmaceutical company filed a lawsuit against the US Food and Drug Administration accusing the regulator of failing to prevent the generic form of Copaxone from going on sale in the US before Teva’s patent on the drug expired. But a federal judge threw out the suit this week, only days after it was filed.
Reports say Copaxone counts for more than 50 percent of Teva’s earnings.
This isn’t the first time Teva has fought to have generic, less expensive rivals from competing. Reports say the company has similarly challenged the release of drugs made by rivals Mylan and Novartis’s Sandoz.
The battle between brand name and generic pharmaceuticals has been a key focus of the Federal Trade Commission as of late; the agency is especially concerned with so-called pay-for-delay agreements, in which a brand name drug maker pays its generic rival to keep the cheaper competitor off store shelves.
Full content: Swiss Info
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
T-Mobile’s Acquisition of Ka’ena Corporation Receives FCC Approval
Apr 26, 2024 by
CPI
UK Regulator Announces Two New Senior Executive Appointments
Apr 26, 2024 by
CPI
Paramount Global and Skydance Media Near Merger Deal, Eyeing CEO Change
Apr 26, 2024 by
CPI
BHP Unveils £31bn Mining Megamerger Proposal with Anglo American
Apr 25, 2024 by
nhoch@pymnts.com
ByteDance Prefers Shutdown Over Sale of TikTok Amid US Ban Threats
Apr 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI